Marpai Valuation

Is MRAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MRAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MRAI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MRAI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRAI?

Key metric: As MRAI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MRAI. This is calculated by dividing MRAI's market cap by their current revenue.
What is MRAI's PS Ratio?
PS Ratio	0.5x
Sales	US$30.29m
Market Cap	US$22.53m

MRAI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	-3.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MRAI's PS Ratio compare to its peers?

The above table shows the PS ratio for MRAI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
HUIZ Huize Holding	0.2x	9.1%	US$33.7m
ZBAO Zhibao Technology	3.3x	36.7%	US$88.9m
MAAL Marketing Alliance	0.6x	n/a	US$11.5m
CCG Cheche Group	0.1x	5.6%	US$70.2m
MRAI Marpai	0.5x	n/a	US$22.5m

Price-To-Sales vs Peers: MRAI is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does MRAI's PS Ratio compare vs other companies in the US Insurance Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
GOCO GoHealth	0.2x	8.0%	US$258.83m
CCG Cheche Group	0.1x	5.6%	US$70.21m
AAME Atlantic American	0.2x	n/a	US$32.44m
CNFR Conifer Holdings	0.2x	n/a	US$14.67m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MRAI is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Insurance industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is MRAI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRAI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MRAI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fairfax Financial Holdings

CA$42.8b

Through its subsidiaries, provides property and casualty insurance and reinsurance, and investment management services in the United States, Canada, Asia, and internationally.

FRFH.F

CA$1,401.10

2.2%

54.5%

Aviva

UK£12.8b

Provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally.

AVVI.Y

UK£12.41

2.6%

16.3%

Markel Group

US$21.8b

A diverse holding company, engages in marketing and underwriting specialty insurance products in the United States, Bermuda, the United Kingdom, and Germany.

MKL

US$1,718.45

0.5%

20.2%